Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

American Journal of Ophthalmology

Volumn 119, Issue 4, 1995, Pages 466-476

  Kirsch, L S ^a   Arevalo, J F ^a   De Clercq, E ^a   De la Paz, E C ^a   Munguia, D ^a   Garcia, R ^a   Freeman, W R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; NUCLEOSIDE ANALOG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MALE; MUSCLE HYPOTONIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETINITIS;

EID: 0028958136     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(14)71233-4     Document Type: Article

References (44)

1. JE Gallant RD Moore DD Richman J Keruly RE Chaisson Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine J Infect Dis 166 1992 1223 1227 the Zidovudine Epidemiology Study Group.
2. AG Palestine MM Rodrigues AM Macher C Chan HC Lane AS Fauci Ophthalmic involvement in acquired immunodeficiency syndrome Ophthalmology 91 1984 1092 1099
3. GN Holland JD Shuler Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients Arch Ophthalmol 110 1992 1435 1442
4. JD Roarty EJ Fisher JJ Nussbaum Long-term visual morbidity of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome Ophthalmology 100 1993 1685 1688
5. JG Gross SA Bozzette WC Mathews SA Spector IS Abramson JA McCutchan Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome Ophthalmology 97 1990 681 686
6. GN Holland JS Pepose HT Pettit MS Gottlieb RD Yee RY Foos Acquired immune deficiency syndrome: ocular manifestations Ophthalmology 90 1983 859 873
7. WR Freeman CW Lerner JA Mines RS Lash AJ Nadel MB Starr A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome Am J Ophthalmol 97 1984 133 142
8. JS Pepose GN Holland MS Nestor M Cochran RY Foos Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease Ophthalmology 92 1985 472 484
9. MA Jacobson JJ O'Donnell D Porteous HR Brodie D Feigal J Mills Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy Q J Med 254 1988 473 486
10. DA Jabs WR Green R Fox BF Polk JG Bartlett Ocular manifestations of acquired immune deficiency syndrome Ophthalmology 96 1989 1092 1099
11. BD Kuppermann JG Petty DD Richman WC Mathews SC Fullerton LS Rickman Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome Am J Ophthalmol 115 1993 575 582
12. DA Jabs C Enger JG Bartlett Cytomegalovirus retinitis and acquired immunodeficiency syndrome Arch Ophthalmol 107 1989 75 80
13. E De Clercq A Holy I Rosenberg T Sakuma J Balzarini PC Maudgal A novel selective broad-spectrum anti-DNA virus agent Nature 323 1986 464 467
14. J Neyts R Snoeck D Schols J Balzarini E De Clercq Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) Virology 179 1990 41 50
15. G Andrei R Snoeck D Schols P Goubau J Desmyter E De Clercq Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus Eur J Clin Microbiol Infect Dis 10 1991 1026 1033
16. S Shigeta K Konno M Baba T Yokota E De Clercq Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro J Infect Dis 163 1991 270 275
17. SB Li ZH Yang JS Feng CK Fong HL Lucia GD Hsiung Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs Antiviral Res 13 1990 237 252
18. FS Stals E de Clercq CA Bruggeman Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine and 9-(13-dihydroxy-2-propoxymethyl) guanine against rat cytomegalovirus infection in vitro and in vivo Antimicrob Agents Chemother 35 1991 2262 2266
19. J Neyts J Balzarini L Naesens E De Clercq Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice J Med Virol 37 1992 67 71
20. DF Smee JL Morris JA Leonhardt JR Mead A Holy RW Sidwell Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl] cytosine, interferon and bropirimine Antimicrob Agents Chemother 36 1992 1837 1842
21. J Neyts H Sobis R Snoeck M Vandeputte E De Clercq Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(13-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice Eur J Clin Microbiol Infect Dis 12 1993 269 279
22. E De Clercq Therapeutic potential of HPMPC as an antiviral drug Rev Med Virol 3 1993 85 96
23. FJ Bravo LR Stanberry AB Kier PE Vogt ER Kern Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs Antiviral Res 21 1993 59 72
24. WL Drew JP Balezari S Glutzer T Lynch J Flaherty JC Martin The safety, pharmacokinetics and anti-CMV activity of weekly HPMPC in HIV positive patients excreting CMV S Michelson SA Plotkin Multidisciplinary approach to understanding cytomegalovirus disease 1993 Excerpta Medica Amsterdam 287 292
25. DR Dolnak D Munguia CA Wiley E De Clercq GL Bergeron-Lynn C Boscher Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine Invest Ophthalmol Vis Sci 33 1992 1557 1563
26. M Flores-Aguilar Huang J-S CA Wiley E De Clercq C Vuong G Bergeron-Lynn Long acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine J Infect Dis 169 1994 642 647
27. Ferris FL III A Kassoff GH Bresnick I Bailey New visual acuity charts for clinical research Am J Ophthalmol 94 1982 91 96
28. AIDS Clinical Trials Group (ACTG) Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial, 1: rationale, design, and methods Control Clin Trials 13 1992 22 39
29. R Snoeck T Sakuma E De Clercq I Rosenberg A Holy (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication Antimicrob Agents Chemother 32 1988 1839 1844
30. JG Gross WR Freeman MH Goldbaum TL Mendez Useful adjuncts for vitreoretinal surgery Br J Ophthalmol 73 1989 435 439
31. YM Mul RT van Miltenburg E De Clercq PC van der Vliet Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein Nucleic Acids Res 17 1989 8917 8929
32. Ho H-T KL Woods JJ Bronson H De Boeck JC Martin MJM Hitchcock Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine Mol Pharmacol 41 1992 197 202
33. I Cochereau-Massin P Lehoang M Lautier-Frau L Zazoun P Marcel M Robinet Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome Ophthalmology 98 1991 1348 1353
34. HL Cantrill K Henry NH Melroe WH Knobloch RC Ramsay Balfour H Jr. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results Ophthalmology 96 1989 367 374
35. Ussery FM III SR Gibson RH Conklin DF Piot EW Stool AJ Conklin Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis Ophthalmology 95 1988 640 648
36. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis N Engl J Med 326 1992 213 220
37. GN Holland MJ Sakamoto D Hardy Y Sidikaro AE Kreiger LM Frenkel Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome: use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)eth-oxymethyl]guanine Arch Ophthalmol 104 1986 1794 1800
38. DA Jabs C Newman S De Bustros BF Polk Treatment of cytomegalovirus retinitis with ganciclovir Ophthalmology 94 1987 824 830
39. GL Daikos J Pulido SB Kathpalia GG Jackson Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression Br J Ophthalmol 72 1988 521 524
40. AG Palestine MA Polis MD De Smet BF Baird J Falloon JA Kovacs A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS Ann Intern Med 115 1991 665 673
41. M Flores-Aguilar BD Kuppermann JI Quiceno WM Dankner DG Wolf EV Capparelli Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis Ophthalmology 100 1993 1022 1031
42. BD Kupperman M Flores-Aguilar JI Quiceno LS Rickman WR Freeman Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus in patients with acquired immunodeficiency syndrome Arch Ophthalmol 111 1993 1359 1366
43. MA Jacobson JJ O'Donnell J Mills Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome Antimicrob Agents Chemother 33 1989 736 741
44. J Schulman GA Peyman MB Horton J Liu R Fiscella J Pulido Intraocular 9-([2-hydroxy-1-(hydroxymethyl) ethoxy]methyl) guanine levels after intravitreal and subconjunctival administration Ophthalmic Surg 17 1986 429 432